Scarica l'app Stockscreener
18.28
0.77%
0.14
Precedente Chiudi:
$18.14
Aprire:
$18.12
Volume 24 ore:
1.05M
Relative Volume:
0.30
Capitalizzazione di mercato:
$4.98B
Reddito:
$426.45M
Utile/perdita netta:
$197.67M
Rapporto P/E:
22.29
EPS:
0.82
Flusso di cassa netto:
$110.10M
1 W Prestazione:
-0.65%
1M Prestazione:
-10.65%
6M Prestazione:
-0.87%
1 anno Prestazione:
+63.07%
Intervallo 1D:
$17.80
$18.39
Intervallo di 1 settimana:
$17.67
$18.91
Portata 52W:
$10.21
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Nome
Adma Biologics Inc
Settore
Industria
Telefono
(201) 478-5552
Indirizzo
C/O ADMA BIOLOGICS, INC., RAMSEY
Confronta ADMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
18.28 | 4.98B | 426.45M | 197.67M | 110.10M | 0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-07-19 | Ripresa | Raymond James | Strong Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2021-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Iniziato | Jefferies | Buy |
| 2019-04-15 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-07 | Ripresa | H.C. Wainwright | Buy |
| 2017-12-11 | Reiterato | Maxim Group | Buy |
| 2017-11-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2016-08-01 | Downgrade | Maxim Group | Buy → Hold |
| 2016-07-25 | Reiterato | Maxim Group | Buy |
| 2015-05-13 | Reiterato | Maxim Group | Buy |
| 2014-12-08 | Iniziato | Oppenheimer | Outperform |
| 2014-12-01 | Reiterato | Maxim Group | Buy |
Mostra tutto
Adma Biologics Inc Borsa (ADMA) Ultime notizie
(ADMA) On The My Stocks Page - news.stocktradersdaily.com
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? - sharewise
ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade) - Seeking Alpha
ADMA Biologics Stock Soars Amid Biotech Growth Nasdaq Composite Gains - Kalkine Media
The 8.3% return this week takes ADMA Biologics' (NASDAQ:ADMA) shareholders three-year gains to 964% - simplywall.st
ADMA Biologics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – ADMA - ACCESS Newswire
Adma Biologics director sells $213,100 in stock - Investing.com Australia
Adma Biologics director sells $213,100 in stock By Investing.com - Investing.com South Africa
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? - Nasdaq
When (ADMA) Moves Investors should Listen - news.stocktradersdaily.com
adma biologics holds annual meeting, elects directors and approves proposals - Investing.com Australia
adma biologics holds annual meeting, elects directors and approves proposals By Investing.com - Investing.com South Africa
ADMA Biologics Holds Annual Stockholders Meeting - TipRanks
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - sharewise
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
Where are the Opportunities in (ADMA) - news.stocktradersdaily.com
Cetera Investment Advisers Decreases Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Adma Biologics director sells $182,635 in common stock - Investing.com Australia
Adma Biologics director sells $182,635 in common stock By Investing.com - Investing.com South Africa
Bank of America Corp DE Has $13.14 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Exploring High Growth Tech Stocks In The US May 2025 - Yahoo
Are Options Traders Betting on a Big Move in ADMA Biologics Stock? - The Globe and Mail
Are Options Traders Betting On A Big Move In ADMA Biologics Stock? - Barchart.com
BNP Paribas Financial Markets Sells 674,016 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
Ameriprise Financial Inc. Acquires 88,542 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Defense World
These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date - The Globe and Mail
(ADMA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
FY2025 EPS Estimates for ADMA Biologics Decreased by Analyst - Defense World
Amid Bumpy Biotech Trade, I'm Eyeing These Two Stocks - TheStreet Pro
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics (NASDAQ:ADMA) Rating Lowered to “Sell” at StockNews.com - Defense World
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - The Globe and Mail
Revenue Gains, Bold Guidance Lift ADMA Shares - FXEmpire
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates - MSN
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics Reports Strong Growth and Strategic Advances - TipRanks
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond - GuruFocus
ADMA Biologics (ADMA) Receives Price Target Upgrade from Raymond James | ADMA Stock News - GuruFocus
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? - Yahoo Finance
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits - MSN
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Adma Biologics price target raised to $32 from $25 at Raymond James - TipRanks
Raymond James Increases Price Target for ADMA Biologics | ADMA Stock News - GuruFocus
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives Propel Future Outlook - GuruFocus
Adma Biologics: Q1 Earnings Snapshot - New Haven Register
ADMA Biologics Reports Strong Q1 2025 Financial Growth - TipRanks
ADMA Biologics Inc earnings missed by $0.01, revenue topped estimates - Investing.com Nigeria
Adma Biologics Inc Azioni (ADMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adma Biologics Inc Azioni (ADMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Jun 16 '25 |
Sale |
20.81 |
21,000 |
437,010 |
2,043,850 |
| ELMS STEVE | Director |
Jun 13 '25 |
Option Exercise |
3.43 |
332,680 |
1,140,763 |
420,010 |
| ELMS STEVE | Director |
Jun 16 '25 |
Sale |
20.24 |
194,749 |
3,941,720 |
87,330 |
| ELMS STEVE | Director |
Jun 13 '25 |
Sale |
20.82 |
137,931 |
2,871,723 |
282,079 |
| ELMS STEVE | Director |
Jun 12 '25 |
Sale |
21.69 |
92,941 |
2,015,890 |
2,031,730 |
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):